Hämosan ® Life Science Services GmbH A-8262 Ilz, Neudorf 41 Tel. +43 (0) 3385/8117 mail: Trainings and much more...

Slides:



Advertisements
Similar presentations
CONTRACT RESEARCH SERVICES 1537 NW 65th Avenue Plantation, FL USA Phone: (954) Fax: (954)
Advertisements

Montpellier - FRANCE. Who are we ? 100% private, family-owned company 48 employees All our products are completely manufactured in our laboratories ISO.
International Research for Global Health NAEJA Pharmaceutical Inc. INTEGRATED MEDICINAL CHEMISTRY.
Prevalence of HBV* by Region
Removal of Prions by Plasma Fractionation Processes
Anaerobic Digestion (AD) A sustainable energy production and waste management solution for your business Robert Crow 30 September 2014.
Innovative Biotech Ltd Nigeria Dr Simon Agwale. General overview (1) n Nigeria is the tenth largest country in the world and the most populous in Africa.
® Bovine Derived Products are Safe TSE Advisory Committee Serologicals Corporation February 2004.
WFH Bangkok 2004 Octanate – Factor VIII with the Safety Factor VWF High Purity Plasma-Derived Factor VIII Double Virus Inactivated Haemophilia A Treatment.
WFH Bangkok 2004 Self-Sufficiency of Plasma Derivatives.
Octaplex – The Modern PCC
1 Douglas C. Lee, PhD Plasma Protein Therapeutics Association BPAC April 2011 Plasma Protein Therapies.
CBER Regulatory Laboratory Planning & Preparedness for SARS-related Biologics Products Kathryn M. Carbone MD Associate Director for Research, Acting, Center.
Nanotechnology in Drug Discovery- Development and Delivery
Biopharmaceutical Production Biopharmaceutical development and GMP manufacturing Professionally sound Reliable Innovative Open Respectful.
Hepatitis B workshop on Identifying Aims, Goals, Gaps, and Priorities for a National Strategy Chronic hepatitis B and associated liver diseases, including.
Good Manufacturing Practices for Blood Establishments
® TSE Advisory Committee The TSE-Safety of Serologicals Products: Use in Global Healthcare Presentation by Serologicals Corporation Wayne E. Vaz Bethesda,
Division of Emerging and Transfusion Transmitted Diseases Bioterrorism Preparedness Initiatives Hira L. Nakhasi, Ph.D.
Antigen antibody reactions
BioLife Plasma Services Experience with HBV NAT Testing
Support to SME’s in US Springboard Americas Eirik Næss-Ulseth
Working with SEPs: How do we expand Hepatitis Services ? Narelle Ellendon, RN HCV Director Harm Reduction Coalition, NYC
NIZO food research in the Food Valley Together to the next level Dr. J. (Koos) Oosterhaven April 27th, 2010.
Prevention and Control of Viral Hepatitis Infection: WHO Framework for Global Action Prevention and Control of Viral Hepatitis Infection: WHO Framework.
20.3 Bacterial & Viral Diseases pg Pathogen- microorganisms that cause disease 2 ways: 1. destroy living cells; tuberculosis- destroys lung tissue.
Pharmaceutical Biotechnology PHT 426
Evaluation of Viral Clearance Studies
MINISTRY OF HEALTH REPUBLIC OF LITHUANIA Can new Member States leap-frog the eHealth revolution? Mrs. Vita Sinicienė Head of Information technology Division.
First author: Madalina Mihailescu Coauthors: Melinda Iakab, Daniela Singeorzan Coordinator: Lecturer Anca Bacarea FREQUENCY OF ACCIDENTS THROUGH OCCUPATIONAL.
1 WHO Communicable Diseases, Surveillance & Response SARS Diagnostics and Laboratory Needs: the WHO Perspective C.E. Roth Dangerous and New Pathogens Global.
NRA in BTSs of the EMR Dr. Nabila E. Metwalli Regional Advisor / Blood Safety WHO / EMRO Cairo, Egypt and Dr. Abdel Aziz Saleh WHO / EMRO Advisor.
Diagnostics Alan S. Rudolph PhD MBA Chief Executive Officer Adlyfe Inc. Rockville, MD Innovation is in our blood Diagnostics.
Removal of Infectious Prions from Red Cell Concentrates Samuel Coker, PhD Principal Scientist and Technical Director Pall Medical Transmissible Spongiform.
Safety of IVIgG Elspeth McIntosh SNBTS Medical Information and Pharmacovigilance Manager.
Validation of Virus Removal Keith O.Webber, Ph.D. Deputy Director, Div. of Monoclonal Antibodies OTRR/CBER/FDA PDA/FDA Meeting September 26, 2000.
Manufacturing Advisory Service South-West Jon Hurrell.
TSE Clearance Studies for pdFVIII: Study Methods and Clearance Levels TSE Advisory Committee September 18, 2006 Dorothy Scott, M.D. Office of Blood Research.
TSE Agent Clearance Issues TSE Advisory Committee February 20, 2003 Dorothy Scott, M.D. DH/OBRR/CBER/FDA.
What do we need GMP compliant facility (R1 billion 2008) Flow, segregation, containment, environmental, statutory Modern technologies for raw material,
TSE Clearance in Plasma Derivatives TSE Advisory Committee February 8, 2005 Dorothy Scott, M.D. DH/OBRR/CBER/FDA.
Graham, North Carolina. History of Biotechnology in North Carolina  Significant Events  1958 – established the Research Triangle.
The Seprion Separation System Development of a feasible blood screening protocol for abnormal prion protein Stuart Wilson Microsens Biotechnologies.
Evaluation of Viral Clearance Studies Mahmood Farshid, Ph.D. Div. Of Hematology OBRR/ CBER/FDA.
The Clinical Trials Network for European Manufacturers Sally Schwarz, MS, RPh, BCNP Chair, Manufacturer’s Registry Sub-Committee SNM Clinical Trials Network.
Minimizing the Risks of TSE Agents in Human Tissues Melissa A. Greenwald, M.D. Division of Human Tissues Office of Cellular, Tissue and Gene Therapies;
Removal of Infectious Prions from Red Cell Concentrates Blood Safety Advisory Committee March 17, 2005 Joseph Cervia, M.D., FACP,FAAP Professor of Clinical.
TSE Task Force Prion reduction evaluation in the manufacturing of plasma protein therapies Dr. Henry Baron, Chair, PPTA TSE Task Force.
Preliminary Risk Assessment Model for U.S. Plasma Derivatives and vCJD Steven Anderson, PhD, MPP Office of Biostatistics & Epidemiology Center for Biologics.
ERT 313 BIOSEPARATION ENGINEERING INTRODUCTION
WEST NILE VIRUS FDA Blood Product Advisory Committee Meeting 13 to 14 March 2003 Dominique Pifat, Ph.D. Bayer Biological Products on behalf of PPTA Viral.
Epidemiology of Transfusion Transmitted Disease Sharyn Orton, MT(ASCP)SBB, M.S.P.H, Ph.D. candidate Project Leader, Transmissible Diseases Department American.
February 24, 2016 | 1 Paul Strengers MD, FFPM Sanquin Blood Supply Amsterdam The Netherlands Risk assessment schemes: Impact of.
1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD Barriers to Pharmaceutical Innovation Richard Laing EDM/PAR WHO.
QUESTOR Centre Applied Technology Unit Julie-Anne Hanna Tipot Kick-Off Meeting September 2004.
Plasma fractionation and viral inactivation/removal procedures
$100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300.
1 Promotion in Management and Research Tracks in Industry Magdalena Alonso-Galicia, PhD Cardiovascular Diseases Department Merck Research Laboratories.
Success Stories of Globalization in Korean Pharma
Hepatitis B immune globulin
Human Parvovirus PARV4 in Blood and Plasma Products
UNIVERSITY OF MINNESOTA
3P Biopharmaceuticals 3P Biopharmaceuticals is a European-based Contract Development and Manufacturing Organization (CDMO) specialized in the process development.
OIE International Standard Reagents: IZSAM experience
Flebogamma® 5% Human Normal Immunoglobulin for Intravenous Administration Pure Confidence.
Marissa Kuzirian, PhD ‘15 Investment Manager
Large Scale Issue for Purification
Viral Safety of Blood Products in Taiwan
Blood borne viral hepatitis action in Wales
PARALAX Life Sciences Investment and Executive Consulting Group of Companies for Innovative Implementation of Medical and Life Science Products and Services.
Presentation transcript:

Hämosan ® Life Science Services GmbH A-8262 Ilz, Neudorf 41 Tel. +43 (0) 3385/8117 mail: Trainings and much more... Herwig Reichl Hämosan Life Science Services GmbH

Hämosan ® Life Science Services GmbH A-8262 Ilz, Neudorf 41 Tel. +43 (0) 3385/8117 mail: Hämosan LSS: Life Science Services Worldwide services for Pharma and Biotech Hämosan is: Hämosan MmQ: Management mit Qualität Coaching Consulting Training

Hämosan ® Life Science Services GmbH A-8262 Ilz, Neudorf 41 Tel. +43 (0) 3385/8117 mail: MmQ Coaching – Consulting – Training Strategy Strategic HRM Leadership Managing Creativity Innovation Development

Hämosan ® Life Science Services GmbH A-8262 Ilz, Neudorf 41 Tel. +43 (0) 3385/8117 mail: HÄMOSAN LSS Viral Safety – QM – Cleanroom Protein purification Viral & prion safety GMP expertise Cleanrooms for Training QM for SMEs, pharmacies etc. –ISO 9001 –ISO 13485

Hämosan ® Life Science Services GmbH A-8262 Ilz, Neudorf 41 Tel. +43 (0) 3385/8117 mail: Our core competence in Hämosan LSS: Safety of Blood Products

Hämosan ® Life Science Services GmbH A-8262 Ilz, Neudorf 41 Tel. +43 (0) 3385/8117 mail: The Need for Safer Products Long history of transmission of bacterial, viral and recently also: prion diseases via blood-derived therapeutics, vaccines, food etc.: Listeria, Salmonella, SV40, HIV, Hepatitis, Parvo B19, vCJD…

Hämosan ® Life Science Services GmbH A-8262 Ilz, Neudorf 41 Tel. +43 (0) 3385/8117 mail: 3 ways to improve safety Screening –is not enough ( log reduction): “diagnostic window“ unknown viruses Testing of end product ( log): –lacks sensitivity; unknown viruses Removal and inactivation steps in manufacturing processes! (> log)

Hämosan ® Life Science Services GmbH A-8262 Ilz, Neudorf 41 Tel. +43 (0) 3385/8117 mail: Validated removal and inactivation steps are required for registration by FDA (USA) EMEA (EU) and all other national authorities Consensus: Several (>2) robust steps capable of removing > 4 logs of infectivity each; Validated with several relevant virus models

Hämosan ® Life Science Services GmbH A-8262 Ilz, Neudorf 41 Tel. +43 (0) 3385/8117 mail: How is it done? 1.Identify possible removal steps in the existing process – if needed, add dedicated ones! 2.Scale down the steps and validate scale-down! 3.Perform validation experiments in safety labs by adding (“spiking“) infectivity and analysing all fractions for it

Hämosan ® Life Science Services GmbH A-8262 Ilz, Neudorf 41 Tel. +43 (0) 3385/8117 mail: Ad 1.: Identification of steps Candidates: Chromatography (AEC!) Heat (wet, dry) Low or high pH Precipitation steps, depth filtration Dedicated steps: Solvent/Detergent treatment Virus (Nano-) Filtration Irradiation (UV, Gamma)

Hämosan ® Life Science Services GmbH A-8262 Ilz, Neudorf 41 Tel. +43 (0) 3385/8117 mail: Ad 2.+3.: Example of a scale- down for process validation: Lab scale: Add 9 ml spike to 81 ml solution; Filtration time: same as at process scale Flow rate per cm²: identical Validate scale-down by comparing products Test all 3 fractions for infectivity! 9000 liter solution Filter 3,6 cm² Filter press: Filter area = 36 m² 9000 liter filtrate Filtercake = waste pump 81 ml 9 90 ml filtrate filtercake pump 90 ml

Hämosan ® Life Science Services GmbH A-8262 Ilz, Neudorf 41 Tel. +43 (0) 3385/8117 mail: Our experience in the field: Scale down validation for all COHN plasma fractionation steps of client Coordinating 4 EU funded research projects focusing on TSE validation 160 virus and prion validation studies for various clients, mainly in blood industry QM and GMP consultancy mainly in (hospital) pharmacies, biotech industry Cleanrooms for practical training (“hands on“!) and pilot scale production (for clinical trials)

Hämosan ® Life Science Services GmbH A-8262 Ilz, Neudorf 41 Tel. +43 (0) 3385/8117 mail: Cleanrooms for training

Hämosan ® Life Science Services GmbH A-8262 Ilz, Neudorf 41 Tel. +43 (0) 3385/8117 mail: Contact: Herwig Reichl Hämosan LSS GmbH Neudorf 41 A-8262 Ilz, Austria